ESR2 and neoplasm: On these bases, and taking into account the availability in the market of several ERβ agonists, we can hypothesize that future research should be aimed at evaluating the potential therapeutic effectiveness of selective ERβ agonists, including natural phytoestrogens or food supplements, in specific combinatory clinical trials with conventional chemotherapeutic agents, aimed at assessing the anti-tumor effects of these agents.